{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T05:40:11Z","timestamp":1758951611261,"version":"3.44.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtha.2025.07.005","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T23:56:59Z","timestamp":1753142219000},"page":"3124-3133","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impaired tolerance in the International Immune Tolerance Induction study due to the presence of very low-titer inhibitors"],"prefix":"10.1016","volume":"23","author":[{"given":"Lars L.F.G.","family":"Valke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles R.M.","family":"Hay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donna M.","family":"DiMichele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Polenewen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marieke J.A.","family":"Verhagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00eblle","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanna R.","family":"Rijpma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole A.M.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saskia E.M.","family":"Schols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7101-8775","authenticated-orcid":false,"given":"Waander L.","family":"van Heerde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.07.005_bib1","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2014from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.005_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2013.06.002","article-title":"Hemophilia A in the third millennium","volume":"27","author":"Franchini","year":"2013","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2025.07.005_bib3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.005_bib4","series-title":"WFH guidelines for the management of hemophilia","first-page":"1","article-title":"WFH Guidelines for the Management of Hemophilia panelists and co-authors","volume":"26","author":"Srivastava","year":"2020"},{"key":"10.1016\/j.jtha.2025.07.005_bib5","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1056\/NEJMoa1803550","article-title":"Emicizumab prophylaxis in patients who have hemophilia A without inhibitors","volume":"379","author":"Mahlangu","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.005_bib6","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1703068","article-title":"Emicizumab prophylaxis in hemophilia A with inhibitors","volume":"377","author":"Oldenburg","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2025.07.005_bib7","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1046\/j.1365-2516.2003.00802.x","article-title":"Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro","volume":"9","author":"Astermark","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.005_bib8","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1160\/TH16-01-0049","article-title":"The burden of inhibitors in haemophilia patients","volume":"116","author":"Walsh","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.005_bib9","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","article-title":"Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group","volume":"102","author":"Gringeri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.005_bib10","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.005_bib11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/0140-6736(93)91593-B","article-title":"Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII","volume":"342","author":"Addiego","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jtha.2025.07.005_bib12","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1182\/blood-2014-08-535328","article-title":"FVIII inhibitors: pathogenesis and avoidance","volume":"125","author":"Astermark","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.005_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2516.2006.01360.x","article-title":"Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors","volume":"12","author":"Astermark","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.005_bib14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2516.2006.01261.x","article-title":"Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia","volume":"12","author":"Astermark","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.005_bib15","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","article-title":"F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis","volume":"119","author":"Gouw","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.005_bib16","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/ejh.12495","article-title":"Genetic risk factors for inhibitors in haemophilia A","volume":"94","author":"Bardi","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2025.07.005_bib17","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1046\/j.1365-2516.2001.00510.x","article-title":"The Malm\u00f6 International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients","volume":"7","author":"Astermark","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.005_bib18","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1055\/s-0038-1649954","article-title":"Haemophilia A: mutation type determines risk of inhibitor formation","volume":"74","author":"Schwaab","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.005_bib19","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.1182\/blood-2006-11-056291","article-title":"Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.005_bib20","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2006-11-056317","article-title":"Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.005_bib21","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1365-2516.2008.01694.x","article-title":"Factor VIII genotype and inhibitor development in patients with haemophilia A: highest risk in patients with splice site mutations","volume":"14","author":"Boekhorst","year":"2008","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.005_bib23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.12091","article-title":"Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization","volume":"160","author":"Collins","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.07.005_bib24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1046\/j.1365-2516.2003.00782.x","article-title":"Control of bleeding in patients with haemophilia A with inhibitors: a systematic review","volume":"9","author":"Lloyd Jones","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.005_bib25","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1365-2516.2003.00779.x","article-title":"The management of inhibitors in haemophilia A: introduction and systematic review of current practice","volume":"9","author":"Paisley","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.005_bib26","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.thromres.2010.10.006","article-title":"Immune tolerance induction in patients with hemophilia A","volume":"127","author":"Astermark","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.07.005_bib27","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/hae.13445","article-title":"Immune tolerance induction: what have we learned over time?","volume":"24","author":"Brackmann","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2025.07.005_bib28","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.transci.2019.08.008","article-title":"Hemophilia A with inhibitor: immune tolerance induction (ITI) in the mirror of time","volume":"58","author":"Nakar","year":"2019","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.jtha.2025.07.005_bib29","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1182\/blood-2011-08-369132","article-title":"The principal results of the International Immune Tolerance Study: a randomized dose comparison","volume":"119","author":"Hay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.005_bib30","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1538-7836.2008.03032.x","article-title":"Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients","volume":"6","author":"Blanchette","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.005_bib31","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bj\u00f6rkman","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.07.005_bib32","first-page":"612","article-title":"Proceedings: a more uniform measurement of factor VIII inhibitors","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1016\/j.jtha.2025.07.005_bib33","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.005_bib34","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1055\/s-0037-1615080","volume":"79","author":"Giles","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.005_bib35","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.005_bib36","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1538-7836.2012.04645.x","article-title":"Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction","volume":"10","author":"Dardikh","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.005_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.thromres.2023.10.007","article-title":"The Nijmegen ultra-sensitive Bethesda assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A","volume":"231","author":"Valke","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.07.005_bib39","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/j.1538-7836.2006.02127.x","article-title":"The international immune tolerance study: a multicenter prospective randomized trial in progress","volume":"4","author":"Dimichele","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.07.005_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-0037-1613759","article-title":"The half-life of infused factor VIII is shorter in hemophiliac patients with blood group O than in those with blood group A","volume":"83","author":"Vlot","year":"2000","journal-title":"Thromb Haemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004283?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625004283?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T05:27:09Z","timestamp":1758950829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625004283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":38,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S1538783625004283"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.07.005","relation":{},"ISSN":["1538-7836"],"issn-type":[{"type":"print","value":"1538-7836"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impaired tolerance in the International Immune Tolerance Induction study due to the presence of very low-titer inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2025 Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}